Skip to navigation Skip to content

Idiopathic pulmonary fibrosis (IPF) Program in Pharmaceutical Benefits Scheme (PBS) 012-18051122

Expand/Collapse all sectionsExpand all


IPF restriction and item codes

Do not share this attachment externally. See Freedom of Information - Freedom of Information - Information Publication Scheme.

\\INTERNAL.DEPT.LOCAL\Shared\NAT\SERDELEXCEL\WORKPRODIMP\Operation Blueprint Migration\RDT Release Icons\32w\icon-hidden-attachment.pngPBS IPF restriction and item codes

Contact details

PBS Complex Drugs Programs team

Form

Idiopathic pulmonary fibrosis - initial authority application form (PB208)

Services Australia website

Idiopathic pulmonary fibrosis

External website

PBS schedule for Idiopathic pulmonary fibrosis

FAQs from Service Officers

Table 1: see Table 2 in Processing Complex Authority Required Listings for FAQs about all Complex programs.

Item

Description

1

Can the pirfenidone 801mg strength be approved for an initial application?

No. Only the 267mg strength can be approved for an initial request as dose titration is required for this medication. Once the 267mg has been approved, the 801mg strength can be approved as continuing treatment.

There is no minimum timeframe between the 267mg and 801mg approval.

Any 'too soon' request for change of strength can be overridden in OPA.

2

Will a change of medication request reject in OPA for being 'too soon'?

A change request may reject as 'too soon' because both medications are in the same treatment group in OPA. However, this can be overridden.